UAE Interventional Cardiology Devices Forecast Report 2025: – GlobeNewswire

Report on the United Arab Emirates Interventional Cardiology Devices Market: 2020-2030

Market Overview and Contribution to Sustainable Development Goals

The United Arab Emirates (UAE) Interventional Cardiology Devices Market is a critical component of the nation’s healthcare sector, demonstrating robust growth and significant alignment with global sustainability objectives. The market was valued at USD 58.25 Million in 2024 and is projected to reach USD 78.42 Million by 2030, expanding at a Compound Annual Growth Rate (CAGR) of 5.08%. This expansion is pivotal for achieving Sustainable Development Goal 3 (SDG 3): Good Health and Well-being, specifically by addressing the high prevalence of cardiovascular diseases (CVDs), a leading cause of mortality in the region. The market’s focus on innovative devices for diagnosing and treating CVDs directly supports SDG Target 3.4, which aims to reduce premature mortality from non-communicable diseases by one-third by 2030.

Furthermore, the market’s development fosters innovation and enhances healthcare infrastructure, contributing to SDG 9: Industry, Innovation, and Infrastructure. Strategic collaborations, such as the awareness campaign by FibriCheck, Pfizer, and Altibbi to detect atrial fibrillation, exemplify SDG 17: Partnerships for the Goals, showcasing how public-private partnerships can advance public health objectives through technology and awareness.

Key Market Drivers

Increasing Prevalence of Cardiovascular Diseases

A primary driver for the market is the rising incidence of CVDs in the UAE, which account for 40% of all deaths. This public health challenge is exacerbated by lifestyle factors prevalent in the population, including:

• Physical inactivity and sedentary lifestyles.
• High rates of overweight or obesity (affecting approximately 71% of adults).
• A high prevalence of diabetes (18.7% of the population).
• Significant tobacco use (9.1% of residents).

The UAE’s Health Vision 2021 and subsequent national health surveys have prioritized the reduction of CVD risk factors and mortality rates. This national commitment, aligned with SDG 3, has led to increased demand for advanced interventional cardiology devices like angioplasty stents, catheters, and structural heart devices. These technologies are essential for providing effective, minimally invasive treatments that improve patient outcomes and support the nation’s public health agenda.

Key Market Challenges

Regulatory Environment and Patient Safety

The regulatory framework, managed by the Ministry of Health and Prevention (MOHAP) and the Emirates Authority for Standardization and Metrology (ESMA), presents a significant challenge. While essential for ensuring patient safety and device efficacy, the complex and stringent approval processes can delay market entry for new technologies. Adherence to these regulations is crucial for maintaining high standards of care and aligns with the broader objectives of SDG 3 to ensure access to safe, effective, and quality medical products. Harmonizing local regulations with international standards like CE Mark and FDA approvals is vital for fostering innovation while safeguarding public health.

Key Market Trends

Adoption of Minimally Invasive Procedures

A dominant trend is the shift towards minimally invasive procedures, such as percutaneous coronary interventions (PCI). This trend is transforming cardiovascular care by offering significant benefits over traditional open-heart surgery, including:

• Reduced patient recovery times and shorter hospital stays.
• Lower risk of complications and post-operative discomfort.
• Improved patient outcomes and quicker return to daily activities.

This shift supports SDG 3 by making advanced cardiac care more efficient and patient-friendly. It also drives SDG 9 by encouraging investment in state-of-the-art healthcare infrastructure, such as advanced catheterization labs, and fostering innovation in medical device technology.

Report Summary

Key Attributes

• Estimated Market Value (2024): USD 58.25 Million
• Forecasted Market Value (2030): USD 78.42 Million
• Compound Annual Growth Rate (CAGR): 5.0%
• Forecast Period: 2024 – 2030
• Regions Covered: United Arab Emirates

Key Market Players

• Medtronic Meta FZ-LLC
• Boston Scientific Corporation
• Abbott Laboratories, S.A.
• Biotronik UAE
• Edwards LifeSciences UAE
• B. Braun Medical Gulf FZ-LLC
• Terumo Middle East FZE
• Cook Medical UAE
• Vasmed UAE
• Life Mate Medical Equipment Trading LLC

Market Segmentation

By Product Type

• Angioplasty Stents
• Angioplasty Balloons
• Catheters
• Structural Heart Devices
• Plaque Modification Devices
• Hemodynamic Flow Alteration Devices
• Others

By End User

• Hospitals & Clinics
• Ambulatory Surgery Centers
• Others

By Region

• Dubai
• Abu Dhabi
• Sharjah
• Rest of UAE

Analysis of Sustainable Development Goals (SDGs) in the Article

1. Which SDGs are addressed or connected to the issues highlighted in the article?

1. SDG 3: Good Health and Well-being
   • The entire article focuses on the interventional cardiology devices market in the UAE, which is dedicated to diagnosing and treating cardiovascular diseases (CVDs). It directly addresses public health challenges, mentioning that CVDs are a “leading cause of mortality in the region” and contribute to “40% of mortality in the United Arab Emirates.” The goal is to improve patient outcomes and cardiovascular health.
2. SDG 9: Industry, Innovation, and Infrastructure
   • The article highlights significant “technological innovations” and “advancements in stent design, materials, and coatings.” It also discusses the expansion of “healthcare infrastructure,” including “hospitals and specialized cardiac centers equipped with state-of-the-art technology.” This points to the development of a resilient and innovative healthcare industry.
3. SDG 8: Decent Work and Economic Growth
   • The report details the economic aspects of the healthcare sector, projecting market growth from “USD 58.25 Million in 2024” to “USD 78.42 Million by 2030.” This growth, driven by innovation and demand, contributes to the country’s economic development. The article also mentions the UAE’s position as a “hub for medical tourism,” which further drives economic activity.
4. SDG 17: Partnerships for the Goals
   • The article provides a specific example of a multi-stakeholder partnership. It states, “In October 2022, FibriCheck collaborated with Pfizer and Altibbi to initiate an awareness campaign aimed at identifying atrial fibrillation (AF) in the UAE.” This collaboration between different entities to achieve a common health goal exemplifies the spirit of SDG 17.

2. What specific targets under those SDGs can be identified based on the article’s content?

1. Under SDG 3 (Good Health and Well-being):
   • Target 3.4: By 2030, reduce by one-third premature mortality from non-communicable diseases through prevention and treatment. The article directly addresses this by focusing on devices and procedures (like angioplasty stents) to treat CVDs, which are a primary non-communicable disease. It notes that the UAE Health Vision 2021 “prioritizes reducing CVD risk factors and mortality rates.”
   • Target 3.d: Strengthen the capacity of all countries… for early warning, risk reduction and management of national and global health risks. The awareness campaign by FibriCheck, Pfizer, and Altibbi, which uses “innovative digital health solutions” like smartphone apps for remote heart rhythm monitoring, is a direct effort to strengthen capacity for “early detection of irregularities” and proactive screening for atrial fibrillation.
2. Under SDG 9 (Industry, Innovation, and Infrastructure):
   • Target 9.5: Enhance scientific research, upgrade the technological capabilities of industrial sectors… and encourage innovation. The article emphasizes “ongoing technological innovations” in the cardiology device market and mentions that the UAE’s health vision prompted “substantial funding allocation towards cardiovascular research initiatives.”
   • Target 9.1: Develop quality, reliable, sustainable and resilient infrastructure… to support economic development and human well-being. The text refers to “government initiatives to expand healthcare infrastructure” and the development of “advanced catheterization labs,” which are critical for delivering modern cardiovascular care and improving well-being.
3. Under SDG 8 (Decent Work and Economic Growth):
   • Target 8.2: Achieve higher levels of economic productivity through diversification, technological upgrading and innovation. The growth of the high-tech interventional cardiology market, with a projected “CAGR of 5.08%,” represents economic diversification and productivity gains driven by technological advancement in the healthcare sector.
4. Under SDG 17 (Partnerships for the Goals):
   • Target 17.17: Encourage and promote effective public, public-private and civil society partnerships. The collaboration between FibriCheck (a technology company), Pfizer (a pharmaceutical company), and Altibbi (a digital health platform) is a clear example of a private-sector partnership aimed at improving public health awareness and outcomes.

3. Are there any indicators mentioned or implied in the article that can be used to measure progress towards the identified targets?

1. For SDG 3 (Good Health and Well-being):
   • Indicator for Target 3.4: The article provides several relevant statistics that serve as indicators. It states that CVDs “contribute to 40% of mortality in the United Arab Emirates.” It also cites key risk factors: “71% of adults and over 30% of children are affected by overweight or obesity,” “diabetes, impacting 18.7% of the population,” and a “smoking rate with 9.1% of residents being smokers.” Tracking these percentages over time would measure progress.
2. For SDG 9 (Industry, Innovation, and Infrastructure):
   • Indicator for Target 9.5: The “substantial funding allocation towards cardiovascular research initiatives” is an indicator of investment in research and development. The continuous introduction of new products like “drug-eluting variants” of stents and “transcatheter heart valves” serves as an outcome indicator of innovation.
3. For SDG 8 (Decent Work and Economic Growth):
   • Indicator for Target 8.2: The article provides clear economic indicators for the market’s growth. These include the “Estimated Market Value (USD) in 2024” of “$58.25 Million,” the “Forecasted Market Value (USD) by 2030” of “$78.42 Million,” and the “Compound Annual Growth Rate” of “5.0%.”
4. For SDG 17 (Partnerships for the Goals):
   • Indicator for Target 17.17: The existence of the partnership itself (“FibriCheck collaborated with Pfizer and Altibbi”) is a qualitative indicator. The initiative’s goal, an “awareness campaign aimed at identifying atrial fibrillation (AF) in the UAE,” can be used to measure the partnership’s scope and impact.

4. Summary Table of SDGs, Targets, and Indicators

Source: globenewswire.com